Navigation Links
Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Date:10/21/2008

or responses needed to proceed to Stage B. In Stage B, the trial is being expanded to include an additional 31 patients, for a total of 46 patients overall. Secondary objectives of the study include assessing time to tumor progression, duration of response, overall patient survival and safety parameters. Patients in the study are evaluated regularly for tumor response according to RECIST criteria.

The World Health Organization reports that breast cancer is the most commonly diagnosed cancer in women, and is second only to lung cancer as a leading cause of female cancer deaths. The National Cancer Institute estimates that approximately 182,460 U.S. women will be diagnosed with breast cancer in 2008 and 40,480 women will die of the disease.

Bavituximab is a monoclonal antibody that binds to the cellular membrane component phosphatidylserine (PS) that is usually located inside cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. By binding to PS, bavituximab is believed to help mobilize the body's immune system to destroy the tumor and the tumor blood vessels. Bavituximab currently is in two separate Phase II combination therapy trials for the treatment of advanced breast cancer and a Phase II combination therapy trial for the treatment of non-small cell lung cancer. A Phase I bavituximab monotherapy trial in advanced solid cancers is also continuing.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis C virus (HCV) infection. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. ('/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
2. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
3. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
4. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
7. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
10. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
11. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/17/2013)... 17, 2013 Z Trim Holdings, Inc. ... providing value-added ingredients to a variety of industries, ... new meat application at this year,s annual Institute ... Chicago , July 13-16. The Company will ... expensive/chemically-modified ingredients in meat products thereby helping manufacturers ...
(Date:6/17/2013)... Yongye International, Inc. (NASDAQ:   YONG) ("Yongye" or the ... nutrient products in the People,s Republic of ... stock will resume trading on the NASDAQ Stock Market ... Time. As previously disclosed, NASDAQ halted trading ... following Yongye,s notification that the filing of its Annual ...
(Date:6/16/2013)... This training is ideal for those who ... the software industry or those who want to explore Agile ... , The topics that will be covered in the 1-day ... meetings, scrum artifacts, and scrum simulation (optional). , The ... CO June 28, 2013 , Click here to register for ...
(Date:6/14/2013)... June 14, 2013 Case Western ... SPR™ Therapeutics, and Valtronic, has been awarded a ... Commission to commercialize a neurostimulation technology platform designed ... needs, including pain and muscle paralysis. ... connects Ohio companies with the technology development and ...
Breaking Biology Technology:Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 2Z Trim to Spotlight New Meat Applications at IFT 2013 in Chicago 3Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 2Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 3Yongye International, Inc. Announces Common Stock Will Resume Trading on the NASDAQ Stock Market on June 17, 2013 4Affordable Scrum Trainings in Denver, CO – 8 PDUs (June 28, 2013) by Conscires Agile Practices 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 2Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 3Case Western Reserve University, in Collaboration with NDI Medical, SPR Therapeutics and Valtronic Technologies, Receives $3 Million from Ohio Third Frontier Commission 4
... , ... wastes has never been easier, or less smelly, thanks to a new indoor composting ... composting bucket collects food scraps in an airtight bucket. Bokashi, made using SCD,s probiotic ... , ...
... May 18 Caliper Life Sciences, Inc. (Nasdaq: CALP ... life sciences research, today announced that it reached an agreement to sell ... product lines to Biotage AB for $16.5 million in cash. ... "Divesting these product ...
... May 17 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. ("Dragon Pharma" or the "Company" ... for the first quarter ended March 31, 2010 . , ... Results for the Quarter Ended March 31, 2010 , ... The Company recorded $49.06 million of revenues for ...
Cached Biology Technology:All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 2All Seasons Indoor Composter™ and All Seasons Bokashi™ Provide Easy Way to Recycle Food Waste Right in Your Kitchen 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 2Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 3Caliper Enhances Strategic Focus and Increases Growth Capital with Sale of Product Lines to Biotage 4Dragon Pharma reports 2010 first quarter financial results 2Dragon Pharma reports 2010 first quarter financial results 3Dragon Pharma reports 2010 first quarter financial results 4Dragon Pharma reports 2010 first quarter financial results 5
(Date:6/14/2013)... the journal Science , Swedish and Australian researchers ... old fossil fishes, revealed by unique fossils from a ... to understand how neck muscles and abdominal muscles ... up a vision of rattling skeletons. Bones and teeth ... usually the only traces of the animal that remain. ...
(Date:6/13/2013)... The World Cultural Council is proud to announce that ... presentations, with its 30th Award Ceremony on Wednesday, 2nd ... and the Programme will be available shortly. , ... criteria for the Science Award of bringing "true benefit ... a scientific leader of several prestigious organizations, with significant ...
(Date:6/13/2013)... MEDFORD/SOMERVILLE, Mass. - Qiaobing Xu, assistant professor of ... was named a Pew Scholar in Biomedical Sciences ... highly competitive program, whose past winners have included ... the Albert Lasker Basic Medical Research Award, identifies ... work focuses on nanotechnology for biomedical uses. He ...
Breaking Biology News(10 mins):2013 World Cultural Council awards 22013 World Cultural Council awards 3Tufts Engineer Qiaobing Xu named 2013 Pew Scholar 2
... Sciences has elected James Birchler, Curators, Professor of Biological ... as a member. Birchler will be inducted into the ... D.C. The National Academy of Sciences is a ... scientific and engineering research, dedicated to furthering science and ...
... (BRONX, NY) There are no effective treatments for rhabdoid tumors ... old and affect the brain or kidneys. The disease is extremely ... the U.S. but is particularly difficult to treat and almost ... of Medicine of Yeshiva University have identified a target for ...
... certain strains of Aspergillus fungi appear to be ... say scientists. University of Manchester researchers, working with colleagues ... not only better diagnose Aspergillus infection, but can ... class of drugs used to treat patients with aspergillosis. ...
Cached Biology News:MU professor elected to membership in National Academy of Sciences 2MU professor elected to membership in National Academy of Sciences 3Einstein researchers find key gene in childhood cancer 2Drug-resistance fears for deadly fungal disease 2
Homo sapiens inhibin, beta B (activin AB beta polypeptide) Antigen: Recombinant Protein(142~254aa)...
Mouse IL-31 RA Biotinylated Affinity Purified PAb...
... High Five cells (BTI-TN-5B1-4) derived ... have been shown to be capable ... secreted recombinant proteins compared to other ... the following features:- -Rapid doubling time as ...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
Biology Products: